Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MRNA

Elizabeth Warren Says Measles Can Hit Record Highs, Slams RFK Jr.'s CDC Panel For Delaying Vaccine: 'How Does That Keep Our Kids Safe?'

Sen. Elizabeth Warren (D-Mass.) on Thursday criticized the Centers for Disease Control and Prevention's vaccine advisory panel following its controversial vote to delay the combined measles, mumps, rubella, and varicella or MMRV vaccine for children under 4 years old.

Benzinga

What's Going On With Moderna Stock Wednesday?

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know.

Benzinga

Moderna Stock Is Moving Higher Tuesday: Here's Why

Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.

Benzinga

Robert Kennedy Jr. Packs CDC Panel With Vaccine Skeptics Ahead of Key Vote On COVID-19 Shots

Health and Human Services Secretary Robert F. Kennedy Jr. has added five new members to the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, just days before it reconvenes to vote on COVID-19 shots and other routine pediatric vaccine recommendations.

Benzinga

Florida Chooses 'Medical Freedom' As State Plans To End Vaccine Mandates, Even For Schools: Experts Warn Of 'Major Disaster' (CORRECTED)

Editor’s Note: This article has been updated to reflect the correct year-to-date performance of Moderna stock.

Benzinga

Is Moderna Stock Underperforming the S&P 500?

With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Elizabeth Warren Slams Trump's CDC Purge: Calls Out RFK Jr's Statements On Measles Vaccines — 'These Fools Can't Be Trusted With Your Health'

Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump’s attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.

Benzinga

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga

Moderna Stock Is Trading Higher Friday: What's Going On?

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher Friday after the company received Health Canada approval for the updated COVID-19 vaccine.

Benzinga

Moderna Is Cutting 10,000 Jobs as Its Business Erodes. How Should You Play MRNA Stock Here?

With vaccine revenue crumbling and layoffs in full swing, is Moderna’s slimmed-down strategy a smart move or a red flag for investors?

Barchart

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies'

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million, marking a major policy shift under Secretary Robert F. Kennedy Jr. that directly affects pharmaceutical giants like Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA).

Benzinga

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Benzinga

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Benzinga

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Barchart

What to Expect From Moderna's Next Quarterly Earnings Report

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Benzinga

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

MarketBeat

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Barchart

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Barchart

Moderna Stock: Analyst Estimates & Ratings

As Moderna has significantly lagged behind the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Barchart

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Barchart

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

MarketBeat

MarketBeat Week in Review – 03/10 - 03/14

Stocks continued to be under pressure on concerns over tariffs and growing inflation concerns, but history shows that corrections can set up opportunities

1 2 3 4 5

People

Gabriel OsorioMazilli

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations